Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Journal of Neuro-Oncology
Published in: Journal of Neuro-Oncology 2/2007

01-06-2007 | Original Paper

Promoter hypermethylation profile of cell cycle regulator genes in pituitary adenomas

Authors: Atsuo Yoshino, Yoichi Katayama, Akiyoshi Ogino, Takao Watanabe, Kazunari Yachi, Takashi Ohta, Chiaki Komine, Takakazu Yokoyama, Takao Fukushima

Published in: Journal of Neuro-Oncology | Issue 2/2007

Login to get access

Abstract

Aberrant hypermethylation of CpG islands in the promoter region plays a causal role in the inactivation of various key genes involved in the cell cycle regulatory cascade, which could result in a loss of cell cycle control. The aim of the present study was to examine in more detail the prevalence and role of the promoter methylation of genes with a proven involvement in the cell cycle regulation of pituitary adenomas, since their tumorigenesis has not yet been clearly defined. We profiled the CpG island methylation status of a series of well-characterized cell cycle regulation genes: the RB1, p14 ARF , p15 INK4b , p16 INK4a , p21 Waf1/Cip1 , p27 Kip1 , and p73 genes, in 34 pituitary adenomas as determined by a methylation-specific polymerase chain reaction assay. Promoter hypermethylation of the RB1, p14 ARF , p15 INK4b , p16 INK4a , p21 Waf1/Cip1 , p27 Kip1 , and p73 genes was detected in 12 (35%), 2 (6%), 11 (32%), 20 (59%), 1 (3%), 0 (0%), and 4 (12%) of the adenomas, respectively. In total, 88% (30 of 34) of the adenomas displayed methylation of at least one of such cell cycle regulatory genes, especially methylation of the member genes of the RB1 pathway (29 of 34; 85%). Promoter hypermethylation of p15 INK4b coincided with RB1 and/or p16 INK4a methylation, whereas RB1 and p16 INK4a methylations tended to be mutually exclusive (p = 0.0048). Furthermore, promoter hypermethylations of p14 ARF , p21 Waf1/Cip1 , and p73 (not belonging to the member genes of the RB1 pathway) were also coincident with RB1 and/or p16 INK4a methylation except in one p73 methylated case. In contrast, none of the clinicopathological features, including the cell proliferation index, was significantly correlated with any particular methylation status. Our results suggested that aberrant hypermethylation of the key cell cycle regulatory genes occurs at a relatively high frequency in pituitary adenomas, especially in RB1 pathway genes with promoter hypermethylation of the p16 INK4a gene being the most common deregulation. We further obtained evidence to indicate that RB1 and p16 INK4a methylations tended to be mutually exclusive, but did occasionally coincide with other cell cycle regulation gene methylations.
Literature
1.
Alexander JM, Biller BMK, Bikkal H et al (1990) Clinically non-functioning pituitary tumors are monoclonal in origin. J Clin Invest 86:336–401PubMed
2.
Herman V, Fagin J, Gonsky R et al (1990) Clonal origins of pituitary adenomas. J Clin Endocrinol Metab 71:1427–1433PubMedCrossRef
3.
4.
Serrano M, Hannon GJ, Beach D (1993) A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 366:704–707PubMedCrossRef
5.
Hannon GJ, Beach D (1994) p15INK4B is a potential effector of TGF-β-induced cell cycle arrest. Nature 371:257–261PubMedCrossRef
6.
7.
Dulic V, Kaufmann WK, Wilson SJ (1994) p53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest. Cell 76:1013–1023PubMedCrossRef
8.
Quelle DE, Zindy F, Ashmun RA et al (1995) Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell 83:993–1000PubMedCrossRef
9.
Kamijo T, Weber JD, Zambetti G et al (1998) Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2. Proc Natl Acad Sci USA 95:8292–8297PubMedCrossRef
10.
Pomerantz J, Schreiber-Agus N, Liegeois NJ et al (1998) The INK4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2’s inhibition of p53. Cell 92:713–723PubMedCrossRef
11.
Zhang Y, Xiong Y, Yarbrough WG (1998) ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 92:725–734PubMedCrossRef
12.
Esteller M, Corn PC, Baylin SB et al (2001) A gene hypermethylation profile of human cancer. Cancer Res 61:3225–3229PubMed
13.
Xu XL, Yu J, Zhang HY et al (2004) Methylation profile of the promoter CpG islands of 31 genes that may contribute to colorectal carcinogenesis. World J Gastroenterol 23:3441–3454
14.
Kawamata N, Inagaki N, Mizumura S et al (2005) Methylation status analysis of cell cycle regulatory genes (p16INK4A, p15INK4B, p21Waf1/Cip1, p27Kip1 and p73) in natural killer cell disorders. Eur J Haematol 74:424–429PubMedCrossRef
15.
Ogino A, Yoshino A, Katayama Y et al (2005) The p15INK4b/p16INK4A/RB1 pathway is frequently deregulated in human pituitary adenomas. J Neuropathol Exp Neurol 64:398–403PubMed
16.
Brüstle O, Ohgaki H, Schmitt HP et al (1992) Primitive neuroectodermal tumors after prophylactic central nervous system irradiation in children: association with an activated K-ras gene. Cancer 69:2385–2392PubMedCrossRef
17.
Herman JG, Graff JR, Myöhänen S et al (1996) Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 93:9821–9826PubMedCrossRef
18.
Nakamura M, Watanabe T, Klangby U et al (2001) p14ARF deletion and methylation in genetic pathways to glioblastomas. Brain Pathol 11:159–168PubMedCrossRef
19.
Watanabe T, Nakamura M, Yonekawa Y et al (2001) Promoter hypermethylation and homozygous deletion of the p14ARF and p16INK4a genes in oligodendrogliomas. Acta Neuropathol 101:185–189PubMed
20.
Watanabe T, Yokoo H, Yokoo M et al (2001) Concurrent inactivation of RB1 and TP53 pathways in anaplastic oligodendrogliomas. J Neuropathol Exp Neurol 60:1181–1189PubMed
21.
Watanabe T, Huang H, Nakamura M et al (2002) Methylation of the p73 gene in gliomas. Acta Neuropathol 104:357–362PubMed
22.
Watanabe T, Katayama Y, Yoshino A et al (2003) Deregulation of the TP53/p14ARF tumor suppressor pathway in low-grade diffuse astrocytomas and its influence on clinical course. Clin Cancer Res 9:4884–4890PubMed
23.
Yoshino A, Katayama Y, Fukushima T et al (2003) Telomerase activity in pituitary adenomas: significance of telomerase expression in predicting pituitary adenoma recurrence. J Neurooncol 63:155–162PubMedCrossRef
24.
Karp JE, Broder S (1995) Molecular foundations of cancer: new targets for intervention. Nat Med 1:309–320PubMedCrossRef
25.
Ng MHL, Chung YF, Lo KW et al (1997) Frequent hypermethylation of p16 and p15 genes in multiple myeloma. Blood 89:2500–2506PubMed
26.
Kamb A, Gruis NA, Weaver-Feldhaus J et al (1994) A cell cycle regulator potentially involved in the genesis of many tumor types. Science 264:436–440PubMedCrossRef
27.
Cairns P, Polascik TJ, Eby Y et al (1995) Frequency of homozygous deletion at p16/CDKN2 in primary human tumours. Nat Genet 11:210–212PubMedCrossRef
28.
Shapiro GI, Park JE, Edwards CD et al (1995) Multiple mechanisms of p16INK4A inactivation in non-small cell lung cancer cell lines. Cancer Res 55:6200–6209PubMed
29.
Ueki K, Ono Y, Hensen JW et al (1996) CDKN2/p16 or Rb alterations occur in the majority of glioblastomas and are inversely correlated. Cancer Res 56:150–153PubMed
30.
Woloschak M, Yu A, Xiao J et al (1996) Frequent loss of the p16INK4a gene product in pituitary tumors. Cancer Res 56:2493–2496PubMed
31.
Farrell WE, Simpson DJ, Bicknell JE et al (1997) Chromosome 9p deletions in invasive and non-invasive non-functional pituitary adenomas: the deleted region involves markers outside of the MTS1 and MTS2 gene. Cancer Res 57:2703–2709PubMed
32.
Yoshimoto K, Tanaka C, Yamada S et al (1997) Infrequent mutations of p16INK4A and p15INK4B genes in human pituitary adenomas. Eur J Endocrinol 136:74–80PubMedCrossRef
33.
34.
Benedict WF, Xu H, Hu S et al (1990) Role of the retinoblastoma gene in the initiation and progression of human cancer. J Clin Invest 85:988–993PubMedCrossRef
35.
Jacks T, Fazeli A, Schmitt EM et al (1992) Effects of an Rb mutation in the mouse. Nature 359:295–300PubMedCrossRef
36.
Hu N, Gutsmann A, Herbert DC et al (1994) Heterozygous Rb-1 delta 20/+ mice are predisposed to tumors of the pituitary gland with a nearly complete penetrance. Oncogene 9:1021–1027PubMed
37.
Cryns VL, Alexander JM, Klibanski A et al (1993) The retinoblastoma gene in human pituitary tumours. J Clin Endocrinol Metab 77:644–646PubMedCrossRef
38.
Woloschak M, Roberts JL, Post KD (1994) Loss of heterozygosity at the retinoblastoma locus in human pituitary tumors. Cancer 74:693–696PubMedCrossRef
39.
Zhu J, Leon SP, Beggs AH et al (1994) Human pituitary adenomas show no loss of heterozygosity at the retinoblastoma gene locus. J Clin Endocrinol Metab 78:922–927PubMedCrossRef
40.
Pei L, Melmed S, Scheithauer B et al (1995) Frequent loss of heterozygosity at the retinoblastoma susceptibility gene (RB) locus in aggressive pituitary tumors: evidence of a chromosome 13 tumor suppressor gene other than RB. Cancer Res 55:1613–1616PubMed
41.
Woloschak M, Yu A, Xiao J et al (1996) Abundance and state of phosphorylation of the Rb gene product in human pituitary tumors. Int J Cancer 67:16–19PubMedCrossRef
42.
Ohta T, Watanabe T, Katayama Y et al (2006) Aberrant promoter hypermethylation profile of cell cycle regulatory genes in malignant astrocytomas. Oncol Rep 16:957–963PubMed
43.
Fero ML, Rivkin M, Tasch M et al (1996) A syndrome of multiorgan hyperplasia with features of gigantism, tumorigenesis, and female sterility in p27kip1 deficient mice. Cell 85:733–744PubMedCrossRef
44.
Kiyokawa H, Kineman RD, Manova-Todorova KO et al (1996) Enhanced growth of mice lacking the cyclin-dependent kinase inhibitor function of p27Kip1. Cell 85:721–732PubMedCrossRef
45.
Nakayama K, Ishida N, Shirane M et al (1996) Mice lacking p27Kip1 display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors. Cell 85:707–720PubMedCrossRef
46.
Lloyd RV, Erickson LA, Jin L et al (1999) p27kip1: a multifunctional cyclin-dependent kinase inhibitor with prognostic significance in human cancers. Am J Pathol 54:313–323
47.
48.
49.
Dahia PL, Aguiar RC, Honegger J et al (1998) Mutation and expression analysis of the p27/kip1 gene in corticotrophin-secreting tumours. Oncogene 16:69–76PubMedCrossRef
50.
Ikeda H, Yoshimoto T, Shida N (1997) Molecular analysis of p21 and p27 genes in human pituitary adenomas. Br J Cancer 76:1119–1123PubMed
51.
Qian X, Jin L, Kulig E et al (1998) DNA methylation regulates p27kip1 expression in rodent pituitary cell lines. Am J Pathol 153:1475–1482PubMed
52.
Loda M, Cukor B, Tam SW et al (1997) Increased proteosome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinoma. Nat Med 3:231–234PubMedCrossRef
53.
Kaghad M, Bonnet H, Yang A et al (1997) Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell 90:809–819PubMedCrossRef
54.
Jost CA, Marin MC, Kaelin WG Jr (1997) p73 is a simian (correction of human) p53-related protein that can induce apoptosis. Nature 389:191–194PubMedCrossRef
55.
Corn PG, Kuerbitz SJ, van Noesel MM et al (1999) Transcriptional silencing of the p73 gene in acute lymphoblastic leukemia and Burkitt’s lymphoma is associated with 5’CpG island methylation. Cancer Res 59:3352–3356PubMed
56.
Ichimiya S, Nimura Y, Kageyama H et al (1999) p73 at chromosome 1p36.3 is lost in advanced stage neuroblastoma but its mutation is infrequent. Oncogene 18:1061–1066PubMedCrossRef
57.
Kawano S, Miller CW, Gombart AF et al (1999) Loss of p73 gene expression in leukemias/lymphomas due to hypermethylation. Blood 94:1113–1120PubMed
58.
Bello MJ, De Campos JM, Isla A et al (2006) Promoter CpG methylation of multiple genes in pituitary adenomas: frequent involvement of caspase-8. Oncol Rep 15:443–448PubMed
59.
Palmero I, Peters G (1996) Perturbation of cell cycle regulations in human cancer. Cancer Surv 27:351–367PubMed
60.
Burns KL, Ueki K, Jhung SL (1998) Molecular genetic correlates of p16, cdk4, and pRb immunohistochemistry in glioblastomas. J Neuropathol Exp Neurol 57:122–130PubMed
61.
Hibberts NA, Simpson DJ, Bicknell JE (1999) Analysis of cyclin D1 (CCND1) allelic imbalance and overexpression in sporadic human pituitary tumours. Clin Cancer Res 5:2133–2139PubMed
62.
Xing EP, Nie Y, Song Y et al (1999) Mechanisms of inactivation of p14ARF, p15INK4b, and p16INK4a genes in human esophageal squamous cell carcinoma. Clin Cancer Res 5:2704–2713PubMed
63.
Garcia MJ, Martinez-Delgado B, Cebrian A et al (2002) Different incidence and pattern of p15INK4b and p16INK4a promoter region hypermethylation in Hodgkin’s and CD30-positive non-Hodgkin’s lymphomas. Am J Pathol 161:1007–1013PubMed
64.
Kwong J, Lo KW, To KF et al (2002) Promoter hypermethylation of multiple genes in nasopharyngeal carcinoma. Clin Cancer Res 8:131–137PubMed
65.
Herman JG, Civin CI, Issa JP et al (1997) Distinct patterns of inactivation of p15INK4b and p16INK4a characterize the major types of hematological malignancies. Cancer Res 57:837–841PubMed
66.
Christiansen DH, Andersen MK, Pedersen-Bjergaard J (2003) Methylation of p15INK4B is common, is associated with deletion of genes on chromosome arm 7q and predicts a poor prognosis in therapy-related myelodysplasia and acute myeloid leukemia. Leukemia 17:1813–1819PubMedCrossRef
Metadata
Title
Promoter hypermethylation profile of cell cycle regulator genes in pituitary adenomas
Authors
Atsuo Yoshino
Yoichi Katayama
Akiyoshi Ogino
Takao Watanabe
Kazunari Yachi
Takashi Ohta
Chiaki Komine
Takakazu Yokoyama
Takao Fukushima
Publication date
01-06-2007
Published in
Journal of Neuro-Oncology / Issue 2/2007
Print ISSN: 0167-594X
Electronic ISSN: 1573-7373
DOI
https://doi.org/10.1007/s11060-006-9316-9

Other articles of this Issue 2/2007

Journal of Neuro-Oncology 2/2007 Go to the issue

Original Paper

Radiation induced peripheral nerve tumors: case series and review of the literature

Clinical Study—patient studies

Aggressive lymphoma involving intracranial epidural region

Original Paper

Alteration of serum and tumoral neural cell adhesion molecule (NCAM) isoforms in patients with brain tumors

Lab Investigation

MGMT prognostic impact on glioblastoma is dependent on therapeutic modalities

Lab Investigation

CD4+CD25+FoxP3+ T-cell infiltration and heme oxygenase-1 expression correlate with tumor grade in human gliomas

Original paper

Expression of Human MCM6 and DNA Topo II α in craniopharyngiomas and its correlation with recurrence of the tumor